000179030 001__ 179030
000179030 005__ 20240229145529.0
000179030 0247_ $$2doi$$a10.1186/s12885-022-09337-2
000179030 0247_ $$2pmid$$apmid:35236321
000179030 0247_ $$2altmetric$$aaltmetric:123979812
000179030 037__ $$aDKFZ-2022-00412
000179030 041__ $$aEnglish
000179030 082__ $$a610
000179030 1001_ $$aKoskinen, Anni I$$b0
000179030 245__ $$aIncidence and survival in oral and pharyngeal cancers in Finland and Sweden through half century.
000179030 260__ $$aHeidelberg$$bSpringer$$c2022
000179030 3367_ $$2DRIVER$$aarticle
000179030 3367_ $$2DataCite$$aOutput Types/Journal article
000179030 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1646822768_1989
000179030 3367_ $$2BibTeX$$aARTICLE
000179030 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000179030 3367_ $$00$$2EndNote$$aJournal Article
000179030 520__ $$aCancers of the oral cavity and pharynx encompass a heterogeneous group of cancers for which known risk factors include smoking, alcohol consumption and human papilloma virus (HPV) infection but their influence is site-specific with HPV mainly influencing oropharyngeal cancer. Their incidence and survival rates are not well known over extended periods of time.Data were obtained for Finnish (FI) and Swedish (SE) patients from the Nordcan database recently updated through 2019. Age-adjusted incidence trends (FI from 1953, SE from 1960) and relative survival rates for years 1970 through 2019 were calculated.We observed a prominent increase in oral and oropharyngeal cancers in FI and SE men and women but the trend for oral cancer was interrupted for SE men in 1985 and possibly also for FI and SE women in 2015. The trend changes in male and female oral cancer was confirmed in data for Denmark and Norway. Relative survival for these cancers has improved overall but they differed for one cluster of oral, oropharyngeal and nasopharyngeal cancers with 60-70% 5-year survival in the last period and hypopharyngeal cancer with 25% male survival. In all these cancers, survival for old patients was unfavorable.We hypothesize that reduction in smoking prevalence helped to stop the increase in oral cancer especially in men. As the prevalence of smoking is decreasing, HPV is becoming a dominant risk factor, particularly for the increasing oropharyngeal cancer. Prevention needs to emphasize sexual hygiene and HPV vaccination.
000179030 536__ $$0G:(DE-HGF)POF4-312$$a312 - Funktionelle und strukturelle Genomforschung (POF4-312)$$cPOF4-312$$fPOF IV$$x0
000179030 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000179030 650_7 $$2Other$$aAlcohol
000179030 650_7 $$2Other$$aHuman papilloma virus
000179030 650_7 $$2Other$$aOral cancer
000179030 650_7 $$2Other$$aPharyngeal cancer
000179030 650_7 $$2Other$$aSmoking
000179030 7001_ $$aHemminki, Otto$$b1
000179030 7001_ $$0P:(DE-He78)f26164c08f2f14abcf31e52e13ee3696$$aFörsti, Asta$$b2$$udkfz
000179030 7001_ $$aHemminki, Kari$$b3
000179030 773__ $$0PERI:(DE-600)2041352-X$$a10.1186/s12885-022-09337-2$$gVol. 22, no. 1, p. 227$$n1$$p227$$tBMC cancer$$v22$$x1471-2407$$y2022
000179030 909CO $$ooai:inrepo02.dkfz.de:179030$$pVDB
000179030 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)f26164c08f2f14abcf31e52e13ee3696$$aDeutsches Krebsforschungszentrum$$b2$$kDKFZ
000179030 9131_ $$0G:(DE-HGF)POF4-312$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vFunktionelle und strukturelle Genomforschung$$x0
000179030 9141_ $$y2022
000179030 915__ $$0LIC:(DE-HGF)CCBYNV$$2V:(DE-HGF)$$aCreative Commons Attribution CC BY (No Version)$$bDOAJ$$d2021-05-04
000179030 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2021-05-04
000179030 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2021-05-04
000179030 915__ $$0StatID:(DE-HGF)0561$$2StatID$$aArticle Processing Charges$$d2021-05-04
000179030 915__ $$0StatID:(DE-HGF)0700$$2StatID$$aFees$$d2021-05-04
000179030 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2022-11-19
000179030 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2022-11-19
000179030 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal$$d2021-02-14T16:18:36Z
000179030 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ$$d2021-02-14T16:18:36Z
000179030 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bDOAJ : Open peer review$$d2021-02-14T16:18:36Z
000179030 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2022-11-19
000179030 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2022-11-19
000179030 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2022-11-19
000179030 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2022-11-19
000179030 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2022-11-19
000179030 9201_ $$0I:(DE-He78)B062-20160331$$kB062$$lB062 Pädiatrische Neuroonkologie$$x0
000179030 9201_ $$0I:(DE-He78)HD01-20160331$$kHD01$$lDKTK HD zentral$$x1
000179030 980__ $$ajournal
000179030 980__ $$aVDB
000179030 980__ $$aI:(DE-He78)B062-20160331
000179030 980__ $$aI:(DE-He78)HD01-20160331
000179030 980__ $$aUNRESTRICTED